{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:17:56Z","timestamp":1759342676157},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.transci.2011.01.018","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T14:19:19Z","timestamp":1298557159000},"page":"223-229","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in myeloma treatment"],"prefix":"10.1016","volume":"44","author":[{"given":"R.","family":"Schots","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2011.01.018_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2011.01.018_b0010","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0015","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2011.01.018_b0020","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0025","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.018_b0035","first-page":"3","volume":"114","author":"Mateos","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V114.22.128.128","article-title":"Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0050","first-page":"613","article-title":"A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma","volume":"114","author":"Palumbo","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0055","first-page":"352","article-title":"The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS","volume":"114","author":"Morgan","year":"2009","journal-title":"ASH Ann Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0060","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","author":"Rajkumar","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0065","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0070","first-page":"354","article-title":"Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexamethasone (VTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"114","author":"Harousseau","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0075","first-page":"351","article-title":"A phase III study of double autotransplantation incorporating bortezomib\u2013thalidomide\u2013dexamethasone (VTD) or thalidomide\u2013dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD","volume":"114","author":"Cavo","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0080","first-page":"653","article-title":"First analysis of HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)","volume":"112","author":"Sonneveld","year":"2008","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.transci.2011.01.018_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.transci.2011.01.018_b0090","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0095","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V114.22.529.529","article-title":"Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the intergroup francophone du myeloma (IFM 2005 02)","volume":"114","author":"Attal","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2011.01.018_b0110","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2011.01.018_b0115","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.018_b0120","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2011.01.018_b0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2011.01.018_b0130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3324\/haematol.11228","article-title":"The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone","volume":"92","author":"Davies","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2011.01.018_b0135","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0140","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib\u2013thalidomide\u2013dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2011.01.018_b0145","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3816\/CLM.2008.n.051","article-title":"Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment","volume":"8","author":"Blade","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.transci.2011.01.018_b0155","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/10428190801930506","article-title":"Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens","volume":"49","author":"Roussou","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2011.01.018_b0160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2011.01.018_b0165","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.018_b0170","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.018_b0175","first-page":"12","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0180","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0185","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.018_b0190","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0195","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0200","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2011.01.018_b0205","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/leu.2010.58","article-title":"Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed\/refractory multiple myeloma","volume":"24","author":"Palumbo","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2011.01.018_b0210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-009-0856-x","article-title":"Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2011.01.018_b0215","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0220","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-009-0726-6","article-title":"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib\/dexamethasone for remission induction in patients with newly diagnosed myeloma","volume":"88","author":"Kropff","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2011.01.018_b0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.2009.07981.x","article-title":"Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma","volume":"148","author":"Bensinger","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2011.01.018_b0230","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.018_b0235","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V114.22.303.303","article-title":"PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort","volume":"114","author":"Siegel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0240","first-page":"127","article-title":"Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM)","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.V114.22.430.430","article-title":"Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects","volume":"114","author":"Vij","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0250","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematol \u2013 Hematol J"},{"key":"10.1016\/j.transci.2011.01.018_b0255","first-page":"311","article-title":"Phase II trial of weekly bortezomib in combination with CCI-779 (temsirolimus) in relapsed or relapsed\/refractory multiple myeloma","volume":"114","author":"Ghobrial","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.018_b0260","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V114.22.432.432","article-title":"Phase 1\/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results","volume":"114","author":"Lonial","year":"2009","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:53:38Z","timestamp":1592344418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050211000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1473050211000346"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2011.01.018","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}